UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Biotechnology is a rapidly growing sector of the United States and global economies. Its products are increasingly important in diagnosis, prevention and treatment of disease. The Master of Science ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

The study enrolled 52 subjects who were randomized ... to time with the Securities and Exchange Commission. Source: Unity Biotechnology, Inc. The views and opinions expressed herein are the ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

UNITY Biotechnology is hosting a virtual investor event to present significant study results, showcasing transparency and engagement with stakeholders. Prominent key opinion leader Robert ...

Claim your 7-Day free trial now. Unity Biotechnology, Inc. UBX stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of ...

In a preclinical study, THIO and its new described dimer ... “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

The broad field of biotechnology and applied microbiology ... Students in this field study genetic engineering; molecular diagnostic and therapeutic techniques; genome data mining; bioprocessing ...

(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics ... who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through ...

Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...

The Boston area is rich in biomedical, pharmaceutical and other biotech companies and organizations. UMass Lowell prepares Biotechnology Option students for careers in this area with practical, ...